Improvement in Sexual Functioning in Patients With Type 2 Diabetes and Depression Treated With Bupropion by Sayuk, Gregory S. et al.
Improvement in Sexual Functioning in
Patients With Type 2 Diabetes and
Depression Treated With Bupropion
GREGORY S. SAYUK, MD, MPH
1,2
BRITT M. GOTT, MS
1 BILLY D. NIX
1
PATRICK J. LUSTMAN, PHD
1,3
OBJECTIVE—Major depressive disorder (MDD) and type 2 diabetes have independent ad-
verse effects on sexual functioning (SF). Bupropion (BU) reportedly has few sexual side effects,
but its use in diabetes has not been studied.
RESEARCH DESIGN AND METHODS—This article reports a planned secondary anal-
ysis of SF in 90 patients with type 2 diabetes treated with BU for MDD.
RESULTS—Atbaseline,71.1%ofpatientshadinsufﬁcientSF.MeanSexualEnergyScale(SES)
scoresimprovedduringtreatment(P,0.0001),asdidthepercentagewithsufﬁcientSF(30.6vs.
68.1%,P=0.001).Patientswithpersistenthyperglycemiahadhigherratesofsexualdysfunction;
however, SES improvement was evident in some with persistent depression or hyperglycemia
(18.2% and 25.9%, respectively).
CONCLUSIONS—Insufﬁcient SF is prevalent and may be suspected in patients with MDD
and type 2 diabetes. BU treatment of MDD had few sexual side effects and was associated with
signiﬁcant improvements in SF.
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T
he adverse effects of diabetes on
sexual functioning (SF) are well es-
tablished. Depression and the med-
ication used to treat it may impose
additional risk of sexual dysfunction in
patients with diabetes (1,2). Bupropion
(BU) has gained favor in major depressive
disorder (MDD) treatment, in part because
of its lower potential for sexual dysfunc-
tion. This article reports a planned second-
aryanalysisofSFdatafromaclinicaltrialof
BU for MDD in patients with type 2 diabe-
tes (3). The aims of this analysis were to
determine the 1) prevalence of sexual dys-
function, 2) occurrence of sexual side ef-
fects with BU treatment, and 3)S F
changes that occur during BU therapy.
RESEARCH DESIGN AND
METHODS—Thisarticlereportson18-
to 80-year-old patients with symptomatic
majordepressiondisorder(MDD)deﬁned
by conventional criteria (4) and type 2 di-
abetes mellitus treated with extended-
release BU in an open-label fashion
over a 10-week study period (3). The pro-
tocolwasapprovedbythe institutionalre-
view board, and all subjects provided
informed consent.
Measures
Demographic, anthropometric, medical,
and diabetes history data were collected
on participants at enrollment. Glycemic
control was measured with A1C. Current
depressionseveritywasassessedusingthe
Beck Depression Inventory (BDI) (5).
M D Dr e m i s s i o nw a sd e ﬁned as a BDI
score of #9 after BU treatment. The Sex-
ual Energy Scale (SES) was used to pro-
vide an ordinal assessment of SF (1–10
scale; 1 = “lowest sexual energy,” 10 =
“highest prior sexual experiences”). SES
scoresof $5 wereregardedas satisfactory
SF, and scores ,5 denoted the presence
of sexual dysfunction (6).
Statistical analyses
Independent sample t tests were per-
formed to assess between-group differ-
ences in continuous variables. x
2 and
Fisher exact tests were performed to de-
termine between-group differences of cat-
egoric variables. Sexual dysfunction and
hyperglycemia evident at both pre- and
posttreatmentarereferredtoas“persistent
sexualdysfunction”and“persistenthyper-
glycemia,” respectively.
RESULTS—Ninety subjects (mean age
51.4 years, 63.3% were female, 46.7%
were Caucasian) were initiated on BU
therapy. Eighteen subjects (19.3%) failed
to complete the study. Baseline rates of
sexual dysfunction were similar between
protocol completers and noncompleters
(P = 0.48). Of the 72 participants who
completedtreatment,61(84.7%)metcri-
teria for MDD remission. Sexual dysfunc-
tionwasevident atbaseline in64 (71.1%)
of the 90 study participants. Of these, 50
completed BU therapy and 28 (56%) ex-
perienced improved SF.
At baseline, participants with sexual
dysfunction were older (52.8 vs. 48.0
years, P = 0.04) and had longer duration
of MDD (25.5 vs. 18.3 years, P = 0.03).
There were no signiﬁcant between-group
differences in depression or A1C. A trend
toward longer duration of type 2 diabetes
existed in those with sexual dysfunction
(7.8 vs. 5.6 years, P = 0.14).
Thosewithpersistentsexualdysfunc-
tion after therapy were older (55.1 vs.
52.0 years, P = 0.11) and had higher A1C
(8.5 vs. 7.1%, P = 0.02). In contrast with
baseline measures, signiﬁcantly higher
BDI scores after therapy were observed
in those with persistent sexual dysfunc-
tion (9.0 vs. 4.9, P =0 . 0 0 7 ) .
SES improved signiﬁcantly during
treatment (SES mean pre- and posttreat-
ment: 3.4–5.6, P , 0.0001), with
51 (70.8%) free of sexual dysfunction
per established SES thresholds. This
represented a signiﬁcant improvement
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vs. 23/72, 31.9%; x
2 = 10.9, P = 0.001).
Although improvement in SF was great-
est in those with gains in depression and
glycemic measures, it was also observed
in two of 11 subjects (18.2%) who did
not achieve depression remission and in
seven of 27 subjects (25.9%) who had
persistently elevated A1C levels (Fig.
1). Nominal improvements in SES after
BU therapy (mean SES change of 0.6 6
1.3) were experienced by those without
improvement in SF. By comparison,
thosewhohadimprovedSFhadaseven-
fold change in SES (4.3 6 1.7, P ,
0.001).
CONCLUSIONS—We found a high
rate (71.1%) of sexual dysfunction in
patients with type 2 diabetes and MDD
despite a modest rate of neuropathy
(22.2%). SF improved signiﬁcantly dur-
ing BU therapy of MDD, with 58% of
subjects experiencing substantial gains in
SF during this interval. This effect was
more robust in those with greater im-
provements in depression and glycemic
control, but was still observed in approx-
imately 20% of those with persistent
MDD or hyperglycemia.
Diabetes may negatively inﬂuence SF
though multiple pathophysiologic path-
ways, that is, vascular, neurologic, and
hormonal effects (7–10). Hyperglycemia
also impairs SF and may have been a fac-
tor in this sample (mean A1C .8%)
(11). MDD imposes additional risk of hy-
perglycemia (12), and indeed, A1C and
BDI scores were positively correlated
both at baseline and after BU therapy. Al-
though depression, A1C, and SF tended
to improve in concert, SF also improved
signiﬁcantly in 25% of those with persis-
tent hyperglycemia.
In persons without diabetes, the risk
of treatment-related sexual dysfunction
is four to six times higher with selective
serotonin- and norepinephrine-reuptake
inhibitors compared with BU (13), pos-
sibly because of BU’sl a c ko fi n ﬂuence
on serotonergic presynaptic reuptake.
Our ﬁndings add to evidence suggesting
low sexual side effects with BU; indeed,
new onset of sexual dysfunction oc-
curred in only one subject. BU augmen-
tation of dopamine effects regarded as
important to arousal and orgasm may
account for observed improvements in
SF (14).
In summary, this study is the ﬁrst to
report on the high rate of sexual dysfunc-
tion in persons with diabetes and de-
pression. Signiﬁcant improvements in
mood, glycemic control, and SF were
observed during BU treatment of MDD.
However, improvement in SF was still
seen in approximately 20% of those with
persistent depression or hyperglycemia.
Limitations of the study relate to its small
samplesize,short-termtreatmentperiod,
open treatment design, and use of a
global measure of SF, the latter preclud-
ing comment on the speciﬁcn a t u r eo f
experienced sexual difﬁculties or im-
provements. Our ﬁndings support the
need for routine assessment of SF in
patients with type 2 diabetes and MDD,
and afﬁrm the importance of mood and
glycemic control in SF. Selection of anti-
depressants with lower sexual side ef-
fects, such as BU, should yield the
greatest potential for sexual and mental
well-being in patients with type 2 di-
abetes and depression.
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